Open filters
Search
Tags
Author
Alison Sathe
Anders Vinther
Barbara W. Unger
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Mark Agostino
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.
Trends

Did COVID-19 Kill Just-in-Time Pharma Supply Chains?

No items found.
Trends

Update: What are Pharma and Med Device Firms Doing About COVID-19?

No items found.
Trends

What All API Manufacturers Need to Know

No items found.
Trends

Identification of Software Validation Shortcomings

No items found.
Trends

Recent Statement Regarding ARB Recalls

No items found.
Trends

Analysis of CDER Report on Pharmaceutical Quality

No items found.
Trends

How Small Pharma Firms Can Prepare for a GMP Inspection in 2019

No items found.
Trends

Data Integrity Trends in 483s and Warning Letters: Part 2

No items found.
Trends

Data Integrity Trends in 483s and Warning Letters: Part 1

No items found.
Trends

FINAL Part 2: How to Stop the Data Integrity Excuses

No items found.
Trends

Part 1: How to Stop the Data Integrity Excuses

No items found.
Trends

“It was the Best Advice Because it was the Worst Advice”

No items found.
Trends

Why Isn’t Paper the Same as Electronic?

No items found.
Trends

FDA Draft Guidance on Multiple Entity Registration Requirements

No items found.
Trends

NASDA and FDA Work Together to Implement the Produce Safety Rule

No items found.
Trends

FINAL Part 3: Invisible Ink in GLP and GCP Research

No items found.
Trends

Part 2: Invisible Ink in GLP and GCP Research

No items found.
Trends

Part 3: Drug GMP Warning Letters Data Integrity

No items found.